<DOC>
	<DOCNO>NCT01297842</DOCNO>
	<brief_summary>Adult patient ESBL-producing Gram negative infection randomize receive ertapenem meropenem/imipenem . Clinical microbiological response group compare .</brief_summary>
	<brief_title>Ertapenem Versus Meropenem/Imipenem ESBL+ Gram-negative Infections</brief_title>
	<detailed_description>Ertapenem active ESBL-producing Gram negative bacteria . This study conduct determine ertapenem effective ESBL-producing Gram negative infection similar meropenem/imipenem .</detailed_description>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Hospitalized patient age &gt; 18 year document ESBL +ve GNB infection Receive meropenem imipenem/cilastatin empiric antibiotic therapy Having treat meropenem imipenem/cilastatin longer 72 hour Have active P. aeruginosa coinfection Pregnancy breast feeding Allergy carbapenems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>